Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

U.S. Biotech/Pharma Sector Daily Observations Letter: February 22, 2018

2018-02-23 seekingalpha
We seem to be trading in a narrow range this week with a break possible in either direction. (10-0)

Sangamo Therapeutics: Great Start To 2018 - $3 Billion KITE Announcement

2018-02-22 seekingalpha
Sangamo Therapeutics (SGMO) reported earnings on 2/22/18, beating the consensus for Q4 by $0.03. They saw a significant increase in their revenues (+44.6% Y/Y) primarily due to revenues related to their strong partnerships with Pfizer (PFE), Bioverativ (BIVV) and Dow Agrosciences (DWDP). They continued their momentum from 2017 into 2018 with the announcements of early safety data for SB-913 in MPS II, an additional tie-up/partnership with PFE, as well as awarding of an exciting grant from the NIH to study T-cell edited antiretrovirals for HIV and finally, a thrilling announcement along with their earnings release of a massive collaboration agreement with KITE, a Gilead company (GILD). (64-0)

Biotechs: Still Well Placed For More Gains

2018-02-20 seekingalpha
Big Pharma has to build out pipelines in new areas, and M&A is a compelling alternative. (719-3)

Challenging Market Timing And 60/40 - The Missing Component

2018-02-20 seekingalpha
At the same time, they discourage those who would even consider timing the market; the topic is taboo. (144-0)

Updating My Bullish Views On Vertex Pharmaceuticals

2018-02-15 seekingalpha
VRTX is an emerging though large-cap biotech with a growing portfolio of drugs for cystic fibrosis. (15-0)

Concert Pharmaceuticals: Expecting Upside From Here

2018-02-14 seekingalpha
Shares have risen substantially since presenting the idea to readers initially. However, it's been a loser since my last update piece. (24-1)

CRSP / CRISPR Therapeutics AG / New Enterprise Associates 15, L.p. - NEA 15 / CRISPR THERAPEUTICS AG - 13G/A - AMEND. #1 (Passive Investment)

2018-02-14 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. 1)*     CRISPR Therapeutics AG (Name of Issuer)     Common Stock, CHF .03 par value per share (Title of Class of Securities)     H17182108 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)             Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐    Rule 13d-1(

CRSP / CRISPR Therapeutics AG / New Enterprise Associates 15, L.p. - NEA 15 / CRISPR THERAPEUTICS AG - 13G/A - AMEND. #1 (Passive Investment)

2018-02-14 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. 1)*     CRISPR Therapeutics AG (Name of Issuer)     Common Stock, CHF .03 par value per share (Title of Class of Securities)     H17182108 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)             Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐    Rule 13d-1(

CRSP / CRISPR Therapeutics AG / GLAXOSMITHKLINE PLC - 3D/A (Activist Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* CRISPR THERAPEUTICS AG (Name of Issuer) Common Shares, Par Value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Number) Victoria A.

CRSP / CRISPR Therapeutics AG / GLAXOSMITHKLINE PLC - 3D/A (Activist Investment)

2018-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* CRISPR THERAPEUTICS AG (Name of Issuer) Common Shares, Par Value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Number) Victoria A.

Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics?

2018-02-09 seekingalpha
Gilead is poised for the upcoming growth with various key catalysts such as NASH, HCV's expansion into China, and CAR-T. (78-0)

CRSP / CRISPR Therapeutics AG / CELGENE CORP /DE/ - SC 13D/A (Activist Investment)

2018-02-08 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)*       CRISPR Therapeutics AG (Name of Issuer)   Common Shares, CHF 0.03 nominal value per share (Title of Class of Securities)   H17182108 (CUSIP Number)   Mark J. Alles Chief Executive Officer Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 (908) 673-9000 (Name, Address and Telephone Number of Person Authorized to Receive Not

CRSP / CRISPR Therapeutics AG / CELGENE CORP /DE/ - SC 13D/A (Activist Investment)

2018-02-08 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)*       CRISPR Therapeutics AG (Name of Issuer)   Common Shares, CHF 0.03 nominal value per share (Title of Class of Securities)   H17182108 (CUSIP Number)   Mark J. Alles Chief Executive Officer Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 (908) 673-9000 (Name, Address and Telephone Number of Person Authorized to Receive Not

Stock Gyrations

2018-02-08 seekingalpha
Is this 1929, the beginning of the end? Or 2007? Is it 1974, annus horribilis in which the stock market drifted down 40% having something to do with stagflation, and did not recover until the 1980s? Is it 1987, a quick dip followed by recovery in a year? Or just an extended version of the flash crash, when the market went down 10% in a few hours, and bounced back by the end of the day? Are we in a "bubble" that's about to burst? How much does this have to do with the Fed? Of course I don't know the answer, but we can think through the logical possibilities. (10-0)


CUSIP: H17182108